V. Moiseyenko

发表

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.

David Miles, Shailendra Verma, Chris Twelves, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice.

R. Zukov, L. Demidov, S. Lazarev, 2021, European journal of cancer.

Clinical trials on adjuvant chemotherapy for breast cancer

V. Semiglazov, R. T. Popova, O. Ivanova, 1986, Cancer.

A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease.

J. Soria, A. Szczesna, P. Zatloukal, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Survival Outcomes in EGFR Mutation-Positive Lung Cancer Patients Treated with Gefitinib until or beyond Progression

E. Imyanitov, E. Preobrazhenskaya, A. Iyevleva, 2016, Oncology Research and Treatment.

CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.

F. Esteva, A. Manikhas, J. Stebbing, 2017, The Lancet. Oncology.

Survival update of so14999 a large phase III trial of capecitabine/doxetaxel combination therapy vs docetaxel monotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC)

D. Miles, L. Mauriac, J. O’Shaughnessy, 2001 .

Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.

E. Van Cutsem, P. Ruff, D. Cunningham, 2015, European journal of cancer.

Results From VELOUR, a Phase 3 Study of Aflibercept (A) Versus Placebo (pbo) in Combination with FOLFIRI for the Treatment of Patients (pt) with Previously Treated Metastatic Colorectal Cancer (MCRC)

J. Tabernero, P. Ruff, C. Allegra, 2011 .

Сonfirmatory study of the efficacy and tolerability of trifluridine/tipiracil (TAS-102) therapy in the Russian population with chemorefractory metastatic colorectal cancer

S. Tjulandin, F. Moiseenko, V. Moiseyenko, 2020, Meditsinskiy sovet = Medical Council.

First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients

A. Sokolenko, E. Imyanitov, E. Preobrazhenskaya, 2018, Clinical Drug Investigation.

Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group.

J. Ajani, C. Boni, E. Van Cutsem, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer

D. Richel, J. Beijnen, W. W. ten Bokkel Huinink, 2004, British Journal of Cancer.

Cell technologies in immunotherapy of cancer.

E. Imyanitov, V. Moiseyenko, A. Danilov, 2007, Advances in experimental medicine and biology.

Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM × Anti-CD3 Antibody: A Phase I/II Study

R. Kimmig, H. Sommer, V. Gorbounova, 2007, Clinical Cancer Research.

Effects of prior bevacizumab (B) use on outcomes from the VELOUR study: A phase III study of aflibercept (Afl) and FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin regimen.

J. Tabernero, P. Ruff, C. Allegra, 2012 .

La adición de aflibercept a fluorouracilo, ácido folínico e irinotecan mejora la supervivencia en un ensayo aleatorizado fase III en pacientes con cáncer colorrectal metastásico tratados previamente con un régimen basado en oxilaplatino

J. Tabernero, P. Ruff, C. Allegra, 2013 .

Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study.

A. Carrato, M. Buyse, J. Ajani, 2013, European journal of cancer.

Phase I–II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma

R. Plummer, R. Andrés, L. Demidov, 2013, British Journal of Cancer.

Rapid Symptomatic Improvement in Gefitinib-Treated Patients with EGFR-Mutated Lung Cancer: Possible Role of Downregulation of Inflammatory Molecules?

E. Imyanitov, V. Moiseyenko, E. Suspitsin, 2011, Oncology Research and Treatment.

Prospective cohort study of clinical characteristics and management patterns for patients with non-small-cell lung cancer in the Russian Federation: EPICLIN-Lung

E. Imyanitov, V. Moiseyenko, S. Tjulandin, 2015, Current medical research and opinion.

Down-Staging of EGFR Mutation-Positive Advanced Lung Carcinoma with Gefitinib Followed by Surgical Intervention: Follow-Up of Two Cases

E. Imyanitov, A. Iyevleva, V. Moiseyenko, 2009, Oncology Research and Treatment.

CCND1 and FGFR1 gene amplifications are associated with reduced benefit from aromatase inhibitors in metastatic breast cancer

E. Imyanitov, A. Iyevleva, S. Aleksakhina, 2020, Clinical and Translational Oncology.

Comprehensive Screening for COVID-19 at St. Petersburg Oncology Centre

F. Moiseenko, V. Moiseyenko, N. Volkov, 2021, Creative surgery and oncology.

Clinical case of the neoadjuvant treatment with nivolumab in a patient with microsatellite unstable (MSI-H) locally advanced gastric cancer

E. Imyanitov, V. Moiseyenko, V. Chubenko, 2020, BMJ Case Reports.

ANALYSIS OF HLA-E EXPRESSION IN HUMAN MELANOMA CELLS

L. Demidov, S. Larin, G. Georgiev, 2006 .

Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial.

D. Miles, L. Mauriac, J. O’Shaughnessy, 2004, Clinical breast cancer.

Tumor acidity: From hallmark of cancer to target of treatment

F. Moiseenko, A. Bogdanov, V. Moiseyenko, 2022, Frontiers in Oncology.

Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): Secondary and subset analyses.

J. Ajani, G. Bodoky, M. Lichinitser, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study

A. Makhson, P. Dubé, P. Hesketh, 2012, Supportive Care in Cancer.

Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.

C. Boni, E. Van Cutsem, J. Tabernero, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC

N. Reinmuth, M. Ahn, S. Peters, 2018, Annals of Oncology.

First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study

E. Van Cutsem, C. Borg, H. Wasan, 2022, British Journal of Cancer.

51A Docetaxel (D), cisplatin (C) 5-fluorouracil (F) compared to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naive patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): Interim results of a randomized phase III trial (V325)

C. Boni, S. Tjulandin, E. Cutsem, 2003 .

Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC)

J. Ajani, C. Boni, S. Tjulandin, 2005 .

NEPTUNE: Phase III Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC.

Ying Cheng, K. Syrigos, N. Rizvi, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

“Lazarus Response” to Olaparib in a Virtually Chemonaive Breast Cancer Patient Carrying Gross BRCA2 Gene Deletion

A. Sokolenko, E. Imyanitov, E. Preobrazhenskaya, 2018, Cureus.

Prevalence of iron deficiency anemia in patients with metastatic colorectal cancer

V. Moiseyenko, A. Zhabina, N. Volkov, 2022, Almanac of Clinical Medicine.

Management and Treatment of Non-small Cell Lung Cancer with MET Alteration and Mechanisms of Resistance.

F. Moiseenko, A. Bogdanov, V. Moiseyenko, 2022, Current treatment options in oncology.

Measurement of DPD and TS Transcripts Aimed to Predict Clinical Benefit from Fluoropyrimidines: Confirmation of the Trend in Russian Colorectal Cancer Series and Caution Regarding the Gene Referees

E. Imyanitov, A. Iyevleva, A. Togo, 2007, Oncology Research and Treatment.

Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy.

D. Peterson, V. Moiseyenko, M. Kopp, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hereditary Breast-Ovarian Cancer Syndrome in Russia

A. Sokolenko, E. Imyanitov, V. Semiglazov, 2010, Acta naturae.

Comparison of the treatment results in patients with inoperable non-small cell lung cancer in clinical trials and in standard clinical practice using the pseudorandomization method

V. Moiseyenko, A. Zhabina, N. Volkov, 2022, Almanac of Clinical Medicine.

Clinical outcome according to tumor HER2 status and EGFR expression in advanced gastric cancer patients from the EXPAND study.

Joon-Oh Park, F. Lordick, Yoon-Koo Kang, 2013 .

A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel.

I. Bondarenko, Y. Shparyk, V. Moiseyenko, 2016, The oncologist.

High efficacy of cisplatin neoadjuvant therapy in a prospective series of patients carrying BRCA1 germ-line mutation

A. Sokolenko, E. Imyanitov, A. Bogdanov, 2015, Medical Oncology.

Evidence for clinical efficacy of mitomycin C in heavily pretreated ovarian cancer patients carrying germ-line BRCA1 mutation

A. Sokolenko, E. Imyanitov, A. Bogdanov, 2014, Medical Oncology.

High sensitivity of BRCA1-associated tumors to cisplatin monotherapy: report of two cases.

A. Sokolenko, E. Imyanitov, E. Kuligina, 2010, Cancer genetics and cytogenetics.

Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines

H. Burger, D. Talbot, D. Talbot, 2002, British Journal of Cancer.

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kazuhiro Yoshida, A. Benson, Y. Bang, 2018, The Lancet.

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

J. Ajani, C. Boni, E. Van Cutsem, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer : A Report of the V 325 Study Group

J. Ajani, C. Boni, Y. Chao, 2006 .

Discrimination between Complete versus Non-Complete Pathologic Response to Neoadjuvant Therapy Using Ultrasensitive Mutation Analysis: A Proof-of-Concept Study in BRCA1-Driven Breast Cancer Patients

A. Sokolenko, E. Imyanitov, A. Iyevleva, 2023, International journal of molecular sciences.

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.

Galina Kurteva, Yoon-Koo Kang, Heiko Götte, 2013, The Lancet. Oncology.

Evidence for predictive role of BRCA1 and bTUBIII in gastric cancer

E. Imyanitov, E. Kuligina, A. Iyevleva, 2013, Medical Oncology.

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer

Edward S. Kim, N. Reinmuth, M. Ahn, 2020, JAMA oncology.

Lack of Response to Vemurafenib in Melanoma Carrying BRAF K601E Mutation

E. Imyanitov, S. Aleksakhina, V. Moiseyenko, 2019, Case Reports in Oncology.

Drug therapy for hereditary cancers

E. Imyanitov, V. Moiseyenko, 2011, Hereditary cancer in clinical practice.

Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma.

J. Ajani, E. Van Cutsem, Y. Chao, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.

E. Van Cutsem, J. Tabernero, P. Ruff, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular-based choice of cancer therapy: realities and expectations.

E. Imyanitov, V. Moiseyenko, 2007, Clinica chimica acta; international journal of clinical chemistry.

EGFR T790M Mutation in TKI-Naïve Clinical Samples: Frequency, Tissue Mosaicism, Predictive Value and Awareness on Artifacts

A. Sokolenko, E. Imyanitov, E. Preobrazhenskaya, 2018, Oncology Research and Treatment.

Resistance mechanisms to drug therapy in breast cancer and other solid tumors: An opinion

M. Dubina, F. Moiseenko, A. Bogdanov, 2017, F1000Research.

EGFR mutation in kidney carcinoma confers sensitivity to gefitinib treatment: a case report.

E. Imyanitov, A. Iyevleva, V. Moiseyenko, 2009, Urologic oncology.

KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience

Sabine Tejpar, István Láng, Gunnar Folprecht, 2008 .

Phase I/II trial of gene therapy with autologous tumor cells modified with tag7/PGRP-S gene in patients with disseminated solid tumors

G. Georgiev, S. Kiselev, A. Barchuk, 2005 .

Minimal PK/PD model for simultaneous description of the maximal tolerated dose and metronomic treatment outcomes in mouse tumor models

V. Klimenko, A. Bogdanov, V. Moiseyenko, 2021, Cancer Chemotherapy and Pharmacology.

Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.

J. Ajani, G. Bodoky, M. Lichinitser, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Variability in lung cancer response to ALK inhibitors cannot be explained by the diversity of ALK fusion variants.

I. S. Sardaryan, E. Imyanitov, E. Filippova, 2018, Biochimie.

Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients.

J. Tabernero, F. Ciardiello, T. Seufferlein, 2016, The oncologist.

Efficacy of immune checkpoint blockade in MUTYH-associated hereditary colorectal cancer

E. Imyanitov, F. Moiseenko, V. Moiseyenko, 2019, Investigational New Drugs.

Monitoring of the presence of EGFR-mutated DNA during EGFR-targeted therapy may assist in the prediction of treatment outcome.

E. Imyanitov, E. Kuligina, V. Moiseyenko, 2022, Cancer treatment and research communications.

An Open-Label Study of the Safety and Efficacy of Tag-7 Gene-Modified Tumor Cells-Based Vaccine in Patients with Locally Advanced or Metastatic Malignant Melanoma or Renal Cell Cancer.

S. Protsenko, G. Georgiev, V. Moiseyenko, 2020, The oncologist.

High Efficacy of First-Line Gefitinib in Non-Asian Patients with EGFR-Mutated Lung Adenocarcinoma

E. Imyanitov, A. Iyevleva, A. Togo, 2010, Oncology Research and Treatment.

Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group.

J. Ajani, C. Boni, E. Van Cutsem, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LAPAROSCOPIC COLORECTAL SURGERY WITH NATURAL ORIFICE SPECIMEN EXTRACTION (NOSE): SINGLE CENTRE EXPERIENCE

V. Moiseyenko, N. Savanovich, A. Smirnov, 2018, Practical oncology.

Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer.

H. Burger, D. Miles, L. Mauriac, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer.

V. Semiglazov, I. K. Seleznev, A. A. Orlov, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy of Videoendoscopic Inguinal Femoral Lymphadenectomy for Management of Metastatic Skin Melanoma

F. Moiseenko, V. Moiseyenko, N. Volkov, 2021, Creative Surgery and Oncology.

Antitumor efficacy of an isolated hind legperfusion with a pH-increased solution in thePliss’ lymphosarcoma graft rat model

A. Bogdanov, V. Moiseyenko, N. Volkov, 2021, Almanac of Clinical Medicine.

46P Intraperitoneal perfusion with sodium bicarbonate solution can significantly increase the lifespan of mice with Ehrlich ascites carcinoma

V. Moiseyenko, N. Verlov, N. Knyazev, 2021, Annals of Oncology.

A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results.

V. Semiglazov, X. Pivot, S. Chatterjee, 2018, European journal of cancer.

Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.

E. Van Cutsem, J. Tabernero, P. Ruff, 2014, European journal of cancer.

Effect of the hydrogen bond on stabilization of the intramolecular structure of comb-like polymers with amide groups in the side chain

V. Moiseyenko, A. L. Smolyanskii, N. Kuznetsov, 1977 .

Incidence of Synchronous Multiple Primary Melanoma in Patients with Solitary Melanoma: a Prospective Comparative Study

F. Moiseenko, V. Moiseyenko, N. Volkov, 2021, Creative surgery and oncology.

Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors

G. Manikhas, S. Tjulandin, U. Keilholz, 2014, Investigational New Drugs.

Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.

V. Semiglazov, X. Pivot, S. Chatterjee, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II dose-finding study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy

I. Bondarenko, Y. Shparyk, V. Moiseyenko, 2015, Medical Oncology.

Current evaluation of the contribution of self-examination to secondary prevention of breast cancer

V. Semiglazov, V. Moiseyenko, 1987, European Journal of Epidemiology.

Study of the role of breast self-examination in the reduction of mortality from breast cancer. The Russian Federation/World Health Organization Study.

V. Semiglazov, V. Moiseyenko, É. A. Mikhailov, 1993, European journal of cancer.

Follow-up for patients with malignancies after radical treatment: unresolved questions

V. Moiseyenko, 2014, memo - Magazine of European Medical Oncology.

Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial

A. Manikhas, J. Stebbing, V. Moiseyenko, 2023, BioDrugs.

Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial

A. Manikhas, J. Stebbing, A. Eniu, 2021, Breast Cancer Research and Treatment.

Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial

J. Stebbing, D. Stroyakovskiy, A. Eniu, 2019, Cancer Chemotherapy and Pharmacology.

Polymers with biphenyl fragments in branches having a crystalline and liquid crystalline structure

N. Platé, V. Moiseyenko, A. L. Smolyanskii, 1981 .

Quality of life in the trastuzumab for gastric cancer trial.

Y. Bang, E. Van Cutsem, Yoon-Koo Kang, 2014, The oncologist.

The role of breast self-examination in early breast cancer detection (results of the 5-years USSR/WHO randomized study in Leningrad)

V. Semiglazov, R. T. Popova, N. Migmanova, 1992, European Journal of Epidemiology.

Abstract CT074: Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): Blood and tissue TMB analysis from MYSTIC, a Phase III study of first-line durvalumab ± tremelimumab vs chemotherapy.

Edward J. Kim, N. Reinmuth, M. Ahn, 2019, Clinical Trials.

Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial.

E. Van Cutsem, P. Ruff, G. van Hazel, 2018, Journal of geriatric oncology.

Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS)

A. Carrato, J. Ajani, J. Jassem, 2015, Journal of Gastrointestinal Cancer.

(Q)-TWiST analysis of trastuzumab plus fluoropyrimidine/cisplatin (T-XP/FP) versus XP/FP alone as first-line therapy for advanced HER2-positive gastric cancer.

Y. Hamamoto, H. Chung, E. Cutsem, 2010 .

Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.

C. Boni, E. Van Cutsem, J. Tabernero, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

KIT mutations in Russian patients with mucosal melanoma

E. Imyanitov, A. Iyevleva, A. Togo, 2011, Melanoma research.

The individualization of treatment based on molecular markers

V. Moiseyenko, 2012, memo - Magazine of European Medical Oncology.

A phase 1b study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with pretreated advanced gastric cancer

S. Tjulandin, V. Moiseyenko, I. Utyashev, 2023, Investigational new drugs.

Analysis of overall survival and safety during the course of the phase III VELOUR trial comparing FOLFIRI and ziv-aflibercept or placebo in mCRC patients who progressed on prior oxaliplatin treatment.

P. Ruff, R. Lakomy, E. Cutsem, 2013 .

Long-term survival rates in cancer patients achieved with metronomic chemotherapy (cyclophosphamide and methotrexate).

F. Moiseenko, V. Moiseyenko, A. Zhabina, 2020 .

High-dose toremifene in advanced renal-cell carcinoma

M. Anttila, V. Moiseyenko, J. Ellmén, 1997, Cancer Chemotherapy and Pharmacology.

Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO)

K. Mcgregor, R. Stahel, S. Peters, 2016, ESMO Open.

Comb-like liquid crystalline polymers with side groups modelling the smectic type of liquid crystal☆

N. Platé, V. Moiseyenko, A. L. Smolyanskii, 1978 .

Tumor irradiation may facilitate the detection of tumor-specific mutations in plasma

E. Imyanitov, E. Stepanova, S. Aleksakhina, 2021, World journal of clinical oncology.

Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC.

Edward S. Kim, N. Reinmuth, M. Ahn, 2019, Journal of Clinical Oncology.

Variability in lung cancer response to ALK inhibitors cannot be explained by the diversity of ALK fusion variants.

I. S. Sardaryan, E. Imyanitov, E. Filippova, 2018, Biochimie.

A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease.

J. Soria, A. Szczesna, P. Zatloukal, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.

S. Hitier, P. Follana, A. Zaniboni, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

P PROGNOSIS IMPACT OF POSTOPERATIVE RADIATION IN PATIENTS WITH RADICAL ESOPHAGECTOMY AND PATHOLOGIC LYMPH NODES POSITIVE ESOPHAGEAL CANCER

J. Reis-Filho, M. Borad, D. Ryan, 2012 .

Efficacy of immune checkpoint blockade in MUTYH-associated hereditary colorectal cancer

E. Imyanitov, F. Moiseenko, V. Moiseyenko, 2019, Investigational New Drugs.